A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection

Phase 4 Unknown 120 enrolled Shandong University

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess efficacy of a new 14-day sequential therapy for the rescue treatment of refractory Helicobacter pylori infection, and whether it is safe while maintaining an ideal eradication rates. The researchers also want to testify whether a double-dose rabeprazole has equal efficacy to double-dose esomeprazole to provide sufficient acid inhibition.

Timeline

Start: 2018-12-15
Primary completion: 2019-08-31
Completion: 2019-10-31

Publications

Liu J, Ji CR, Li YY, Qiao C, Hu JN, Wan M, Lin MJ, Lin BS, Wang J, Zha J, Li LX, Zuo XL. Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study. Clin Transl Gastroenterol. 2021 Aug 16;12(8):e00391. doi: 10.14309/ctg.0000000000000391.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Esomeprazole	Small molecule	40 mg	—
Comparator	Rabeprazole	Small molecule	20 mg	—
Background	Amoxicillin	Other / unclassified	1000 mg	—
Background	Furazolidone	Small molecule	100 mg	—
Background	Tetracycline	Unknown	500 mg	—
Background	colloidal bismuth pectin	Unknown	200 mg	—

A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection

Summary

Timeline

Publications

Drugs

Indications